ZimVie — Q1 2023 Earnings Presentation
11 slides from ZimVie's earnings presentation, May 3, 2023
Slide 1: Supplemental Financial Information
Supplemental Financial Information May 3, 2023 Exhibit 99.2
Slide 2: Forward-Looking Statements and Non-GAAP Measures
FORWARD-LOOKING STATEMENTS AND NON-GAAP MEASURES Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This presentation contains forward-looking statements within the meaning of federal securities laws, including, among others, any statements about our expectations, plans
Slide 3: 1Q 2023 Results
1Q 2023 Results 14.3% Adjusted EBITDA Margin[1] $0.25 Adjusted Diluted EPS[1] Third Party Net Sales: $225.1M Adjusted EBITDA[1]: $32.1M Adjusted Net Income[1]: $6.7M [1] This is a Non-GAAP financial measure. Refer to the reconciliation in the Appendix for further information. $120.2M in Dental Third
Slide 4: 2023 Full-Year Financial Guidance
2023 Full-Year Financial Guidance Line Item 2023 Guidance Net Sales* $835M - $860M Gross Margin[1] Mid-to-High 60%s Adjusted EBITDA Margin[1] 13.5% - 14.0% Interest Expense $37M - $39M Stock-Based Compensation $21M - $23M Adjusted Effective Tax Rate[1] 26.0% Fully Diluted Shares Outstanding 28.6M Ad
Slide 5: Appendix
Bendix 2 ZimVie
Slide 6: Note on Non-GAAP Financial Measures
Note on Non-GAAP Financial Measures This presentation includes non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures may not be comparable to similar measures reported by
Slide 7: Net Sales by Region and Segment
ZimVie NET SALES BY REGION AND SEGMENT (in thousands) For the Three Months Ended March 31, 2023 2022 Change (%) Foreign Exchange Impact Constant Currency % Change United States $ 69,907 $ 68,329 2.3% - 2.3% International 50,263 52,240 -3.8% -4.9% 1.1% Total Dental Net Sales 120,170 120,569 -0.3% -2.
Slide 8: EBITDA
ZimVie RECONCILIATION OF ADJUSTED EBITDA (in thousands) [1] In June 2022 and November 2022, we instituted restructuring plans and the expenses incurred under these plans were primarily related to employee termination benefits and the exit of our spine products operations in China as a result of an u
Slide 9: Gross Profit and Margin
ZimVie RECONCILIATION OF ADJUSTED GROSS PROFIT AND MARGIN (in thousands) [1] One-time expenses captured through allocations made for purposes of the GAAP carve-out financial statement results. [2] One-time share-based compensation expense due to replacement awards provided in connection with the sep
Slide 10: R&D and SG&A
ZimVie RECONCILIATION OF ADJUSTED R&D AND SG&A (in thousands) [1] Expenses incurred for initial compliance with the EU MDR for previously-approved products. [2] One-time-share-based compensation expense due to replacement awards provided in connection with the separation from Zimmer Biomet. [3] Refl
Slide 11: Net Income (Loss) and Adjusted EPS
ZimVie RECONCILIATION OF ADJUSTED NET INCOME (LOSS) AND ADJUSTED EPS (in thousands, except per share data) [1] Reflects certain items captured in the GAAP carve-out financial statements that have not continued post-spin, including, but not limited to, facilities that did not convey with ZimVie in th